Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Parainfluenza Virus

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Parainfluenza Virus. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
7.7%
death-coded share
Dog
most-reported species
5
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
1
Deaths Reported
7.7%
Death Rate

Active Ingredients

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Parainfluenza Virus

Administration Routes

NasalSubcutaneous

Species Affected

Dog 13

Most Affected Breeds

Retriever - Golden 2
Spitz - German Pomeranian 2
Dachshund (unspecified) 1
Terrier (unspecified) 1
Pinscher - Miniature 1
Terrier - Welsh 1
Terrier - Fox Wire 1
Poodle - Toy 1
Dachshund - Miniature 1
Terrier - Bedlington 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 5
Fever 5
Other abnormal test result NOS 5
Skin disorders NOS 3
Anorexia 3
Vomiting 3
Pruritus 2
Skin scab 2
Lack of efficacy - NOS 2
Diarrhoea 2
Injection site lump 2
Urticaria 2

Outcome Breakdown

Ongoing
11 (84.6%)
Recovered/Normal
1 (7.7%)
Died
1 (7.7%)

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Parainfluenza Virus Adverse Event Insights

13 reports name Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Parainfluenza Virus; 1 recorded a death outcome (7.7% of reported events, not a population-level mortality rate). Active ingredient: Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Parainfluenza Virus. Administration routes: Nasal, Subcutaneous.

By species: Dog (13 reports). By breed: Retriever - Golden (2), Spitz - German Pomeranian (2), Dachshund (unspecified) (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (5), Fever (5), Other abnormal test result NOS (5), Skin disorders NOS (3). Outcome, 13 coded reports: Ongoing leads at 84.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.